Abstract View

Author(s): S. Apoorva1*1, Dr. B. Veeresh22, G. Harshini23, Fatima Mirza34

Email(s): 1sapoorva27101996@gmail.com

Address:

    1 Department of Pharmaceutical Chemistry, G. Pulla Reddy College of Pharmacy, Hyderabad, India. 2 Department of Pharmacology, G. Pulla Reddy College of Pharmacy, Hyderabad, India.

Published In:   Volume - 4,      Issue - 5,     Year - 2025

DOI: https://doi.org/10.71431/IJRPAS.2025.4505  

 View HTML        View PDF

Please allow Pop-Up for this website to view PDF file.

ABSTRACT:
Acute myeloid leukaemia (AML) is an aggressive hematologic malignancy characterized by uncontrolled proliferation of immature myeloid cells, often leading to poor prognosis and high relapse rates. It remains challenging to treat due to resistance driven by anti-apoptotic proteins BCL-2 and MCL-1, which inhibit apoptosis by stabilizing the mitochondrial membrane. Venetoclax, a BCL-2 inhibitor, faces resistance due to MCL-1 upregulation. This study evaluates five novel inhibitors—AZD5991, BRD-810, BFC1108, VU661013, and A-1210477—that target both BCL-2 and MCL-1 to overcome Venetoclax resistance. Computational tools Molinspiration and SwissADME predicted favourable physicochemical and pharmacokinetic properties for these compounds, with BFC1108 showing the best gastrointestinal absorption. ChemDraw was used for chemical structure representation, and Autodock vina 1.5.7 performed molecular docking with 6QBC (MCL-1) and 6FBX (BCL-2). Docking results showed strong binding affinities of all the compounds and exclusively, with AZD5991 binding to MCL-1 similarly to Venetoclax binding to MCL-1. A-1210477 showed superior binding to BCL-2, suggesting potential as a potent complement. Biovia visualized protein-ligand interactions, supporting dual inhibition of BCL-2 and MCL-1 as an effective strategy to induce apoptosis in AML cells resistant to Venetoclax. In conclusion, AZD5991, BRD-810, BFC1108, VU661013, and A-1210477 are promising dual inhibitors for AML treatment. Computational analysis suggests they may overcome Venetoclax resistance with favourable pharmacokinetic profiles.

Cite this article:
S. Apoorva, Dr. B. Veeresh, G. Harshini, Fatima Mirza.In Silico Studies of Novel BCL-2 and MCL-1 Inhibitors Using Computational Drug Design Tools. IJRPAS, May 2025; 4 (5): 46-60DOI: https://doi.org/https://doi.org/10.71431/IJRPAS.2025.4505


We acknowledge the help of G. Pulla Reddy College of Pharmacy, Hyderabad, in providing the required infrastructure and facilities to conduct this in silico research study. We thank the Department of Pharmacology and the Department of Pharmaceutical Chemistry for their technical support and guidance during the work. We further acknowledge the informative feedback and inspiration provided by S. Apporva, Assistant Professor, Department of Pharmaceutical Chemistry, and Dr. Veeresh B., Professor and Head, Department of Pharmacology, as our corresponding authors.

REFERENCES       

1) Yamashita M, Dellorusso PV, Olson OC, Passegué E. Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis. Nat Rev Cancer. 2020;20(7):365–82.

2) Orkin SH, Zon LI. Hematopoiesis: an evolving paradigm for stem cell biology. Cell. 2008;132(4):631–44.

3) Wilson A, Laurenti E, Oser G, van der Wath RC, Blanco-Bose W, Jaworski M, et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell. 2008;135(6):1118–29.

4) Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, Chen K, et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med. 2012;366(12):1090–8.

5) Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011;118(7):1723–35.

6) Jan M, Snyder TM, Corces-Zimmerman MR, Vyas P, Weissman IL, Quake SR, et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med. 2012;4(149):149ra118.

7) Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150(2):264–78.

8) Bose P, Grant S. Mcl-1 as a therapeutic target in acute myelogenous leukemia (AML). Leuk Res Rep. 2013;2(1) 12–14

9)  Dhakal P, Bates M, Tomasson MH, Sutamtewagul G, Dupuy A, Bhatt VR. Acute myeloid leukemia resistant to Venetoclax-based therapy: What does the future hold? Blood Rev. 2023;59:101036.

10) Ramsey HE, Fischer MA, Lee T, Gorska AE, Arrate MP, Fuller L, et al. A Novel MCL1 Inhibitor Combined with Venetoclax rescues Venetoclax-Resistant Acute Myelogenous Leukemia. Cancer Discov. 2018;8(12):1566-81.

11) Hird AW, Tron AE. Recent advances in the development of Mcl-1 inhibitors for cancer therapy. Pharmacol Ther. 2019;198:59–67

12) Wei Y, Zhao M. Targeting Bcl-2 Proteins in Acute Myeloid Leukemia. Front Oncol. 2020; 10:584974.

13) Mabkhot YN, Alatibi F, El-Sayed NNE, Al-Showiman S, Barakat A, Al-Obaid AM, et al. Antimicrobial activity of some novel armed thiophene derivatives and PETRA/OSIRIS/Molinspiration (POM) analyses. Molecules. 2016;21(2):222.

14) Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717.

15) Dmitry A Filimonov , Anastassia V Rudik , Alexander V Dmitriev , Vladimir V Poroikov. Computer-aided estimation of biological activity profiles of drug substances. Biomed Res Ther. 2020;7(10):4029–40.

16) Stephen K Burley , Helen M BermanJose M DuarteZukang FengJustin W FlattBrian P Hudson, et al. Protein Data Bank: a comprehensive review of 3D structure data resources. Nucleic Acids Res. 2023;51(D1): D488–D508.

17) Rizvi SM, Shakil S, Haneef M. A simple click by click protocol to perform docking: AutoDock 4.2 made easy for non-bioinformaticians. EXCLI J. 2013;12:831–57.

Related Images:



Recent Images



Gas Chromatographic Profiling and Characterization of Essential Oils from Ocimum tenuiflorum
Artabotrys hexapetalus (I.F) Bhandari: A Phytoconstituent And Pharmacological Review
Fava beans: An Ancient Tool to Manage Parkinson’s Disease
Impact of AI on Pharmacovigilance: A Systematic Review
Neuroprotective Potential of Fenugreek and Black Cumin in Alzheimer’s Disease: A Comprehensive Review
In Silico Studies of Novel BCL-2 and MCL-1 Inhibitors Using Computational Drug Design Tools
Formulation and Evaluation of Soap by using Goat Milk and other Herbals
Formulation and Evaluation of Transdermal Patches Containing Metformin for the Management of Gestational Diabetes
Formulation and evaluation of polyherbal cough syrup
Formulation and Evaluation of a Polyherbal Anti-Dandruff Shampoo Using Traditional Medicinal Plants

Tags


Recomonded Articles:

Author(s): Pravin V. Gomase; R. R. Patil; Sunil P. Pawar

DOI: NA         Access: Open Access Read More

Author(s): Mohammad Zaid*; Prof. Imran Kalam; Dr. Quazi Majaz

DOI:         Access: Open Access Read More

Author(s): Quazi Kamil Hafiz Anees Ahemad; Dr. Majaz Quazi; Quazi Wasil; Dr. G. J. Khan

DOI:         Access: Open Access Read More

Author(s): Adebayo T. Bale; Abdulfatai T. Ajiboye; Isiaka A. Idiaro

DOI:         Access: Open Access Read More

Author(s): Vaibhav S. Jadhav; Vishwajeet G. Thorat; Priyanka V. Gawali; Dr. Balmukund R. Rathi

DOI:         Access: Open Access Read More

Author(s): Ansari Owais Ahmad; Pradeep Kumar Mohanty; Pradeep Kumar Yadav

DOI:         Access: Open Access Read More

Author(s): Baburao Mohite; Manisha Mane; Sarika Suryavanshi; Shrirang Kharmate; Pranali Patil; Anand Gadad.

DOI:         Access: Open Access Read More

Author(s): Musab Khan; Saad Ahmad Khan; Pathan Faizan Khan; Mochi Muzammil; Mohammad Saqib Usmani

DOI:         Access: Open Access Read More

Author(s): Pathan Ayyaj Magbul; Khalifa Mahmadasif Y.; Shaikh Museb; Shaikh Arbaz Ajaz; Shaikh Md. Aman; Shaikh Faisal.

DOI:         Access: Open Access Read More

Author(s): J. J. Naik

DOI:         Access: Open Access Read More

Author(s): Khatik Avej; Khanushiya Maaz; Khan Adil; Khairdi Mohd. Ubaid

DOI:         Access: Open Access Read More

Author(s): Mudigonda Sowjanya*; Nishad, Fariya; Malla Rajeshwari; Dr. K. Lakshmi Surekha

DOI:         Access: Open Access Read More

Author(s): Ankit Yadav; Neeraj kumar; Abhishek Kumar; Chetan; Ajay kumar Garg.

DOI:         Access: Open Access Read More

Author(s): Sanket Kailas Bhimsen*; Pushpak Jitendra Borase; Sanjot Hemant Chaudhari.

DOI: https://doi.org/10.71431/IJRPAS.2025.4416         Access: Open Access Read More

Author(s): Sayed Anasali Israrali*, Dr. Quazi Majaz Ahamad Aejazuddin, Abuzar Khan, Mansuri Jahid Siraj.

DOI:         Access: Open Access Read More

Author(s): Dr. Shaikh Muzaffar Ahmed1;* Dr. Gufran Ahmad Qamruddin2; Dr. Sumaira Abdul Salam3;

DOI:         Access: Open Access Read More

Author(s): M Sohil M Shabbir; Shaikh Imran Kalam; Aejaz Ahmad; G.J. Khan; Md Moiz; Aman Shaikh

DOI:         Access: Open Access Read More

Author(s): Pradnya P. Patil; Ankita S. Bhadane; Devesh P. Bhavsar

DOI:         Access: Open Access Read More